| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0024-3205(82)90132-1 |
| P953 | full work available online at | https://api.elsevier.com/content/article/PII:0024320582901321?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:0024320582901321?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 6131357 |
| P2093 | author name string | R. A. Lahti | |
| P. F. VonVoigtlander | |||
| VonVoigtlander PF | |||
| C. Barsuhn | |||
| P2860 | cites work | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 | ||
| Chronic naloxone results in prolonged increases in opiate binding sites in brain | Q40177996 | ||
| 3H-ethylketocyclazocine binding: Lack of evidence for a separate κ receptor in rats CNS | Q40285609 | ||
| Dynorphin Is a Specific Endogenous Ligand of the κ Opioid Receptor | Q44352111 | ||
| Bremazocine: A potent, long-acting opiate kappa-agonist | Q46629270 | ||
| High affinity binding of [3H]ethylketocyclazocine to rat brain homogenate | Q72148483 | ||
| P433 | issue | 20-21 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 4 | |
| P304 | page(s) | 2257-2260 | |
| P577 | publication date | 1982-11-01 | |
| 1982-11-15 | |||
| P1433 | published in | Life Sciences | Q5256275 |
| P1476 | title | Properties of a selective kappa agonist, U-50,488H | |
| P478 | volume | 31 |
| Q33869693 | A cell-based, high-throughput homogeneous time-resolved fluorescence assay for the screening of potential κ-opioid receptor agonists |
| Q68258330 | A kappa opiate agonist, U50, 488H, enhances energy expenditure in rats |
| Q44338592 | Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse |
| Q44349908 | Activity of the δ-Opioid Receptor Is Partially Reduced, Whereas Activity of the κ-Receptor Is Maintained in Mice Lacking the μ-Receptor |
| Q44352546 | Affinities of some common opioid analgesics towards four binding sites in mouse brain |
| Q71852415 | Anti-inflammatory effects of kappa-opioids in adjuvant arthritis |
| Q44350679 | Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys |
| Q35754811 | Bremazocine differentially antagonizes responses to selective mu and delta opioid receptor agonists in rat hippocampus |
| Q42028208 | Cardiovascular actions of the κ‐agonist, U‐50,488H, in the absence and presence of opioid receptor blockade |
| Q44352684 | Characterization of kappa1-opioid receptor binding in human insular cortex |
| Q35237319 | Chemical structures and biological activities of non-peptide selective kappa opioid ligands |
| Q44351416 | Delta and mu opioid receptors from the brain of a urodele amphibian, the rough-skinned newt Taricha granulosa: cloning, heterologous expression, and pharmacological characterization |
| Q44347810 | Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration |
| Q41864970 | Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats |
| Q28379331 | Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal |
| Q43978577 | Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones |
| Q44335235 | Dynorphin A-( 1-13)-Tyr14Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective κ opioid peptide |
| Q42715007 | Effect of opioid receptor subtype-selective agonists on purinergic and adrenergic components of neurogenic contractions of mouse vas deferens |
| Q73865949 | Endogenous opiates in the chick retina and their role in form-deprivation myopia |
| Q44343222 | Enhancement of blood-brain barrier permeability to sodium fluorescein by stimulation of mu opioid receptors in mice |
| Q44336555 | Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 3: Synthesis of decahydro(iminoethano)phenanthrene derivatives with an oxygen functionality at the 3-position and their pharmacologies |
| Q43774611 | Evaluation of the effects of opioid agonists and antagonists under a delayed matching-to-sample procedure in pigeons |
| Q37227174 | Evaluation of the effects of specific opioid receptor agonists in a rodent model of spinal cord injury |
| Q34496610 | Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats |
| Q44332663 | In vivo modulation of post-spike excitability in vasopressin cells by kappa-opioid receptor activation |
| Q43640234 | Inducible HSP70 mediates delayed cardioprotection via U-50488H pretreatment in rat ventricular myocytes |
| Q69350003 | Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions |
| Q48623087 | Intrathecal administration of dynorphin A and its fragments increase heart rate and arterial pressure in the urethane anesthetized rat: mediation by a nonopioid mechanism |
| Q44340949 | Involvement of kappa-opioid receptors in peripheral response to nerve stimulation in kappa-opioid receptor knockout mice |
| Q38312641 | Kappa Opioid Receptor Agonist and Brain Ischemia |
| Q44352932 | Kappa-opioid receptor activation inhibits post-spike depolarizing after-potentials in rat supraoptic nucleus neurones in vitro |
| Q43869162 | Long-acting fentanyl analogues: synthesis and pharmacology of N-(1-phenylpyrazolyl)-N-(1-phenylalkyl-4-piperidyl)propanamides. |
| Q44345751 | Modulation of feline bladder and distal urethral responses to dorsal sacral root stimulation by intrathecal administration of a kappa 1-opioid agonist |
| Q35027469 | Neuroregulation of mucus secretion by opioid receptors and KATP and BKCa channels in ferret trachea in vitro |
| Q47838207 | Neurotransmitter-mediated changes in the electrophysiological properties of pituicytes |
| Q37660087 | New therapeutic potential for psychoactive natural products |
| Q44351684 | Opioid receptor subtypes involved in the central inhibition of urinary bladder motility |
| Q40139515 | Opioid regulation of CNS dopaminergic pathways: A review of methodology, receptor types, regional variations and species differences |
| Q83285774 | Pharmacology of a new tritiated endomorphin-2 analog containing the proline mimetic cis-2-aminocyclohexanecarboxylic acid |
| Q28138587 | Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist |
| Q42054397 | Protection by U-50,488H against β-chlornaltrexamine antagonism of nitrous oxide antinociception in mice |
| Q39468417 | Receptors in the dorsal horn and intrathecal drug administration |
| Q69022182 | Release of substance P from the cat spinal cord |
| Q44334609 | Renal responses to the kappa-opioid-receptor agonist U-50488H in conscious lambs |
| Q43263805 | Role of protein kinase C-epsilon in the development of kappa-opioid receptor tolerance to U50,488H in rat ventricular myocytes |
| Q41527783 | Sensitization to the Behavioral Effects of Cocaine: Modulation by Dynorphin and κ-Opioid Receptor Agonists |
| Q43647880 | Sex differences in opioid antinociception: kappa and 'mixed action' agonists |
| Q48190709 | Striatal neurochemistry of dynorphin-(1-13): in vivo electrochemical semidifferential analyses |
| Q43070634 | Structure-activity relationship studies of dynorphin A and related peptides |
| Q44336656 | Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 3, novel propellane derivatives with pentacyclic skeletons |
| Q44333623 | Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology. Part 2: Propellane derivatives with an amide side chain |
| Q39422689 | Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists |
| Q34578586 | The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system |
| Q54597380 | The effect of U-50,488H, A κ-opiate receptor agonist on tolerance to the analgesic and hyperthermic effects of morphine in the rat |
| Q68936189 | The histamine-releasing effect of dynorphin and other peptides possessing Arg-Pro sequences |
| Q44352442 | The opioid κ-selective compound U−50,488H does not inhibit intestinal propulsion in rats |
| Q33890721 | The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse |
| Q34132638 | The role of κ-opioid receptor activation in mediating antinociception and addiction |
| Q31965867 | The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. |
| Q56566621 | U-50,488 and the к receptor: A personalized account covering the period 1973 to 1990 |
| Q44333654 | Ventral tegmental injections of a selective μ or δ opioid enhance feeding in food-deprived rats |
| Q44350434 | κ-Opioid Regulation of Neuronal Activity in the Rat Supraoptic NucleusIn Vivo |
Search more.